This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter that integrates two critical PAD treatments into a single device. The innovative feature of the Philips catheter is that both the atherectomy and lithotripsy are laser-driven. clinical trial,” said Dr.
The Neuroguard Integrated Embolic Protection (IEP) system is an experimental treatment for carotid artery stenosis, also known as carotid artery disease, a condition in which fatty-waxy deposits known as plaque builds up and blocks the normal flow of blood in the large arteries on either side of the neck.
Roche has an unrivaled ability to provide access to testing at scale and is committed to advancing innovation in preventive cardiology. More than 90% of the Lp(a) level is influenced by variations in the genes controlling the Lp(a) particle production, 2 in which lifestyle interventions such as diet and exercise have no significant impact.
At present, machine learning, deep learning, and other AI technologies have been tried to be applied to intelligent diagnostic and decision making, image interpretation, accurate classification, and prognostication of cardiovascular diseases, which has led to broad application prospects and innovation potential.
The breakthrough designation, according to the Milpitas, CA-based technology company, is for an indication to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. of the U.S. population.
6 This novel study marks a significant milestone in the field, evaluating the effectiveness of FFR CT in detecting ischemia-producing coronary stenosis in patients with severe PAD. Journal of Vascular Surgery Cases, Innovations and Techniques, vol. 101272, [link].
Previous to GWU, Earls served as Medical Director and Vice President at Fairfax Radiological Consultants (FRC) in Fairfax, VA, where he was an early innovator and clinical adopter of coronary CT angiography. With Plaque Features Associated with False Positives. Barcelona, Spain. 4 Chiou A, Hermel M, Miller G et al.
Nevertheless, the relationship between CAC and the susceptibility of a plaque to provoke a thrombotic event remains incompletely understood. Limited spatial resolution and blooming artifacts may hinder estimation of degree of coronary artery stenosis. This review summarizes the current understanding and literature on CAC.
24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.
Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content